NMN vs NR: Which NAD+ Booster Actually Works?

NMN vs NR: An Evidence-Based Comparison of NAD+ Boosters

NAD+ (nicotinamide adenine dinucleotide) has moved from the biochemistry textbook to mainstream supplement culture with remarkable speed. Discussions of cellular ageing, sirtuin activation, and longevity are increasingly accompanied by questions about how best to raise NAD+ levels through supplementation. Two molecules dominate the conversation: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both are NAD+ precursors, both are commercially available, and both have been subject to human clinical trials. But they are not identical, and the differences matter when choosing between them.

Why NAD+ Declines With Age

NAD+ is a coenzyme present in every cell, participating in hundreds of metabolic reactions including the transfer of electrons in mitochondrial energy production, the activation of sirtuins (NAD+-dependent deacylases linked to cellular stress responses and longevity pathways), and the activity of PARPs (poly-ADP-ribose polymerases) involved in DNA repair. It is not simply a static metabolite — it is consumed and must be continuously regenerated.

NAD+ levels in human tissues decline with age by roughly 40–50% between the ages of 40 and 80, measured in blood and skin biopsies. The exact causes are debated but likely include increased consumption by CD38 (an NAD+ hydrolase that rises with age-related inflammation), reduced activity of biosynthetic enzymes such as NAMPT, and accumulated DNA damage increasing PARP demand. The consequence is a fall in the energetic and signalling capacity of cells, particularly in energy-demanding tissues like muscle, brain, and liver.

The Biosynthetic Routes: Where NR and NMN Fit

Both NR and NMN feed into the salvage pathway of NAD+ biosynthesis:

- NR is taken up by cells and phosphorylated to NMN by NRK1/NRK2 (nicotinamide riboside kinases), and NMN is then adenylated to NAD+ by NMNAT enzymes. - NMN is one step further along this pathway, closer to NAD+. However, NMN cannot directly enter cells — it must first be dephosphorylated to NR at the cell surface by CD73 (or related ectonucleotidases), then taken up as NR and re-phosphorylated intracellularly. Recent research has also identified a dedicated NMN transporter (Slc12a8) in intestinal cells and potentially elsewhere, which may allow direct cellular uptake in certain tissues.

This distinction has driven considerable debate about whether NMN's extra phosphate group confers any advantage or disadvantage versus NR at a physiological level. The short answer, based on current human data, is that both reliably raise blood NAD+ levels and appear to have comparable efficacy.

Human Trial Evidence: NR

NR has the longer human clinical history. The 2016 study by Trammell and colleagues published in Nature Communications was the first randomised, double-blind crossover trial in healthy adults, demonstrating dose-dependent increases in blood NAD+ with NR supplementation at 100mg and 300mg daily. Importantly, the researchers used metabolomics to confirm that NR raised NAD+ and its metabolites (including NAAD, a particularly sensitive marker) rather than simply increasing nicotinamide.

Subsequent trials have examined NR across a range of populations. A 2018 trial in older adults by Martens and colleagues (Cell Metabolism) found that NR at 500mg daily for six weeks raised blood NAD+ by approximately 60% and reduced some markers of inflammation, with no significant adverse effects. Trials in people with Parkinson's disease, heart failure, metabolic syndrome, and cognitive decline have followed, with generally consistent findings on NAD+ elevation and variable clinical outcomes depending on the endpoint.

Human Trial Evidence: NMN

NMN entered human trials more recently, partly because of regulatory delays and partly because earlier preclinical work focused heavily on mouse models. A 2020 Japanese pilot study by Yamauchi and colleagues published in npj Aging and Mechanisms of Disease was the first double-blind RCT in humans, showing that NMN at 100mg, 250mg, and 500mg daily was safe and well tolerated over 12 weeks, with dose-dependent NAD+ increases in blood.

A 2022 trial by Yi and colleagues published in GeroScience examined NMN at 300mg daily in middle-aged and older adults, finding significant increases in blood NAD+ and improvements in muscle function and walking speed compared to placebo — a clinically meaningful endpoint.

A notable 2023 study in amateur runners found NMN improved oxygen utilisation and endurance performance, suggesting functional benefits beyond simple biomarker changes.

Comparing Efficacy: What the Data Says

No head-to-head randomised trial of NMN versus NR has been published to date — the critical comparison that would definitively answer which is superior at raising NAD+ or producing clinical outcomes. Based on available data, both compounds reliably elevate blood NAD+ at doses of 250–500mg daily. The magnitude of increase appears broadly comparable. NR has more published trials and longer follow-up data. NMN has more recent momentum and some trials suggesting functional endpoints.

The argument that NMN is "one step closer to NAD+" and therefore superior has not been borne out in practice — the CD73 dephosphorylation step appears to be efficient enough that this does not constitute a bottleneck in healthy adults.

Dosing and Practical Considerations

Both NR and NMN are typically dosed at 250–500mg daily. Taking them in the morning may align better with circadian NAD+ metabolism, though no trial has definitively established a timing advantage. Both are fat-soluble enough to be taken with or without food, though food may improve tolerance.

Cost varies: NMN is generally more expensive than NR per gram. Both are available from multiple manufacturers, and quality control varies considerably — choosing products with third-party testing is advisable.

Safety

Both compounds have good safety profiles across all published human trials, with no serious adverse events attributed to treatment. NR can elevate liver enzymes at very high doses in some individuals; NMN trials have not reported this. Neither compound should be conflated with nicotinic acid (niacin) or plain nicotinamide, which have different profiles.

Bottom Line

NR and NMN are both legitimate, evidence-supported NAD+ precursors that reliably raise blood NAD+ levels in human trials. NR has a more established trial record; NMN has more recent clinical data including some functional endpoints. At 250–500mg daily, either represents a reasonable choice for someone seeking to support NAD+ status — particularly from mid-life onward when natural decline becomes physiologically significant.